Arrowhead Files IND for RNAi Therapeutic ARC-520 to Begin Phase 2b Multiple-Dose Studies in Chronic Hepatitis B Patients | 6:30 AM |
[Business Wire] - Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it submitted an Investigational New Drug application to the U.S.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.